Cargando…

Endobronchial Metastases in Lung Cancer Harboring EML4-ALK Rearrangement

Detalles Bibliográficos
Autores principales:	Ijichi, Miharu, Fukuda, Yosuke, Kashima, Ayaka, Sagara, Hironori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2022
Materias:	Pictures in Clinical Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372270/ https://www.ncbi.nlm.nih.gov/pubmed/36351589 http://dx.doi.org/10.2169/internalmedicine.0941-22

Ejemplares similares

Successful treatment of extensive-stage small cell lung cancer with concurrent pleural and pericardial effusions: Case report
por: Kashima, Ayaka, et al.
Publicado: (2022)

Thyroid metastasis from lung adenocarcinoma with EML4-ALK rearrangement
por: Kawamoto, Hironori, et al.
Publicado: (2016)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib
por: Chung, Jon H., et al.
Publicado: (2014)

Endotracheal Metastases of Lung Cancer with Refractory Wheezing
por: Chiba, Yosuke, et al.
Publicado: (2019)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Tree-in-bud Pattern in ALK-positive Lung Adenocarcinoma
por: Shiroyama, Takayuki, et al.
Publicado: (2020)

Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
por: Kwon, Ji-Hyun, et al.
Publicado: (2019)

Cutaneous metastases of lung cancer
por: Fukuda, Yosuke, et al.
Publicado: (2019)

Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement
por: Liang, Long, et al.
Publicado: (2021)

CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma
por: An, Rong, et al.
Publicado: (2016)

Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
por: Paliouras, Athanasios R, et al.
Publicado: (2020)

Endobronchial Lipoma: The Diagnostic Benefit of Computed Tomography Findings
por: On, Rintaro, et al.
Publicado: (2017)

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene
por: Tanaka, Hisashi, et al.
Publicado: (2012)

Duodenal Metastases from Lung Carcinoma
por: Mori, Atsushi, et al.
Publicado: (2017)

EML4-ALK rearrangement of lung large cell neuroendocrine carcinoma: a case report
por: Chen, Dianjun, et al.
Publicado: (2023)

Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non‐EML4‐ALK rearrangements detected from cerebrospinal fluid: A case report
por: Li, Zhaona, et al.
Publicado: (2019)

Efficacy of Additional Corticosteroids After Dexamethasone Treatment for Moderate to Severe COVID-19: An Observational Study
por: Fukuda, Yosuke, et al.
Publicado: (2023)

Case Report: Early Distant Metastatic Inflammatory Myofibroblastic Tumor Harboring EML4-ALK Fusion Gene: Study of Two Typical Cases and Review of Literature
por: Han, Qianqian, et al.
Publicado: (2022)

EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report
por: von Buttlar, Xinyu, et al.
Publicado: (2021)

EML4-ALK rearrangement in primary malignant fibrous histiocytoma of the lung treated with alectinib: A case report
por: Zhang, Shuai, et al.
Publicado: (2022)

Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4‐ALK fusion gene
por: Kometani, Takuro, et al.
Publicado: (2018)

Imported Tungiasis in a Non-endemic Country
por: Adachi, Eisuke, et al.
Publicado: (2018)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
por: Huang, Ming-Hung, et al.
Publicado: (2022)

Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis: A Case Report
por: Wang, Wenxian, et al.
Publicado: (2016)

Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib
por: Guo, Weihong, et al.
Publicado: (2022)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Response to ALK‐TKIs in a lung adenocarcinoma patient harboring dual DCTN1‐ALK and ALK‐CLIP4 rearrangements
por: Gao, Fangfang, et al.
Publicado: (2022)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer
por: Nilsson, R. Jonas A., et al.
Publicado: (2015)

Unilateral Ptosis Caused by Pancreatic Neuroendocrine Tumour Metastases
por: Ueno, Tatsuya, et al.
Publicado: (2018)

Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review
por: Chen, Qin, et al.
Publicado: (2023)

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
por: Lin, Yen-Ting, et al.
Publicado: (2019)

Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
por: Papageorgiou, Savvas, et al.
Publicado: (2022)

A non-functional 5′ ALK fusion validated at the RNA level as a classical EML4-ALK that responds well to the novel ALK inhibitor ensartinib: A case report
por: Yang, Hong, et al.
Publicado: (2022)

Clinicopathologic Features of Patients with Non-Small Cell Lung Cancer Harboring the EML4-ALK Fusion Gene: A Meta-Analysis
por: Wang, Ying, et al.
Publicado: (2014)

Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements
por: Pisano, Chiara, et al.
Publicado: (2022)

In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line
por: Nanjo, Shigeki, et al.
Publicado: (2015)

Clinicopathological and Prognostic Significance of EML4-ALK Rearrangement in Patients with Surgically Resected Lung Adenocarcinoma: A Propensity Score Matching Study
por: Shi, Jinghan, et al.
Publicado: (2020)

Clinicopathological Characteristics of Patients with Non-Small-Cell Lung Cancer Who Harbor EML4-ALK Fusion Gene: A Meta-Analysis
por: Zhao, Fengzhi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ol0o71kauhg1fkur6avl4225gg